Company intelligence / Profile preview

EmphyCorp Inc.

Flemington, New Jersey, United Statesemphycorp.com ↗

Ownership: Private
Development stage: Phase 3

Overview

Completed three successful Phase III clinical trials for N115 Nasal Spray for Pulmonary Fibrosis, COVID-19, and COVID-19 Long Haulers treatments. The product has demonstrated efficacy with no known side effects in all lung and sinus diseases tested. N115 produced statistically significant increases in lung functions with reduction in inflammation, oxygen radicals, congestion, coughing, fatigue, and inflammatory cytokines including IL-6.

Therapeutic areas: PulmonologyOncologyImmunologyNeurologyInfectious Diseases
Modalities: Non-steroidal nasal sprayoral spray
Industry: Biotech

Drug pipeline

2 assets

sodium pyruvate nasal spray

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on EmphyCorp Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EmphyCorp Inc..

Explore the full profile